(PRWEB) July 09, 2012
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit alleging that Plavix caused severe hemorrhaging in an Oklahoma man. The suit, which names Bristol-Myers Squib Company, Sanofi-Aventis U.S., L.L.C., Sanofi US Services, Inc., and Sanofi-Synthelabo, Inc as Defendants, was filed on June 29th in the Supreme Court of the State of New York, County of New York (Index No. 154117/2012).
According to the complaint, the Plaintiff took Plavix from March 2010 to November 2010. He suffered from two gastrointestinal hemorrhages and one cerebral hemorrhage-the most recent of these injuries occurred in December 2010, when he suffered his second gastrointestinal bleed. The lawsuit alleges that the Plaintiff experienced several adverse effects as a result of Plavix’s defects, including severe and permanent injuries, physical impairment and disfigurement, physical pain and suffering, mental pain and suffering, loss of enjoyment of life and past, present and future sums of money incurred from medical expenses associated with monitoring and treating his injuries.
Plavix is an antiplatelet drug that has been on the US market since 1997. It is used to reduce the risk of atherosclerotic events such as blood clot, stroke and heart attack in patients with a history of these conditions. According to the complaint, the Defendants have profited enormously from the blood-thinning medication. The lawsuit states that Plavix has generated approximately $42.8 billion in sales since it was introduced.
Plavix’s financial success was the driving force behind the Defendants’ negligent and fraudulent actions, the suit alleges. The lawsuit claims that the Defendants were aware that Plavix increased the risk of serious bleeding events, but continued to sell the drug to protect their financial interests. The suit also alleges that the Defendants made false and unsubstantiated claims when marketing Plavix when claiming that it is superior to Aspirin in lowering the rate of blood clots, stroke and heart attack. According to the complaint, the drug makers have also insisted that Plavix is safe when used in combination, or “dual-therapy” with Aspirin and that is preferable because it is more tolerable on the gastrointestinal system.
However, the lawsuit points out that there are several research findings to contradict the Defendants’ claims about Plavix. In 2005, the New England Journal of Medicine (NEJM) published a study showing that patients who took Plavix had a much higher rate of recurring ulcer bleeding compared to patients who took Aspirin plus a heartburn pill. The Defendants’ marketing claims were again called into question in 2006, when the NEJM published another study. This time, researchers looked at the effects of dual therapy with Aspirin plus Plavix, and found that the combination had no significant benefits at preventing atherosclerotic events compared to Aspirin alone.
Parker Waichman LLP continues to offer free legal consultations to victims of alleged Plavix side effects, including:
- Cerebral hemorrhage
- Thrombotic Thrombocytopenic Purpura (TTP)
- Gastrointestinal bleeding
- Internal bleeding
- Bone marrow damage
- Heart attack
If you or a loved experienced serious, life-threatening internal bleeding, heart attacks, strokes, or a blood disorder, and you believe Plavix is to blame, please contact their office by visiting the firm's Plavix side effects page at yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
For more information regarding Plavix side effects lawsuits and Parker Waichman LLP, please visit: yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).
Parker Waichman LLP
Gary Falkowitz, Managing Attorney